跳至主要内容
临床试验/NCT00728403
NCT00728403Unknown2 期

Long Term Metabolic and Therapeutic Effects of Combined Treatment of American Ginseng (Panax Quinquefolius L.) Extract and Korean Red Ginseng (Steamed Panax C.A. Meyer) Extract in the Treatment of Type 2 Diabetes

Unity Health Toronto2 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2008年9月最近更新:
适应症

试验速览

阶段
2 期
入组人数
120
试验地点
2
主要终点
HbA1c levels and insulin sensitivity index using 3 different indices: ISI, HOMA, QUICKI

研究概览

简要总结

The study is a 2 phase double blind randomized placebo control trial. The objective is to asses the metabolic and therapeutic effects of American Ginseng (Panax quinquefolius L.) extract and Korean Red Ginseng (steamed Panax C.A. Meyer) extract in the management of type 2 diabetes in a 12 week period. One Hundred and twenty subjects with type 2 diabetes (hyperglycemia key inclusion criteria: HbAlc≥6.5% - ≤ 8.1% ) will participate in the study (36 men and 36 post-menopausal women).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
40 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • presence of type 2 diabetes (at least 1 year) as defined by A1c between ≥6.5% and ≤8.1%, at recruitment,
  • treatment with diet or oral hypoglycemic medication be unchanged starting at least 2 months prior to the beginning of the study (at recruitment, week -8)
  • between the age of 40 and 75 years
  • systolic blood pressure <140 and diastolic blood pressure <90
  • clinically euthyroid (measuring T3 and T4)
  • normal renal and liver functions
  • post-menopausal or non-pregnant women (Post-menopausal includes: those females with more than a year of cessation of menstruation)
  • a negative result on a pregnancy test administered at screening
  • subjects taking an effective form of birth control (example: condom, abstinence, etc.)
  • willing to comply with the study protocol and sign a consent form

排除标准

  • individuals with bleeding disorders
  • individuals with allergies to nitroglycerin
  • planned surgery, pregnancy or breastfeeding
  • taking insulin; clinically significant diabetes complications (retinopathy, nephropathy, or neuropathy); serum triglycerides ≥ 4.5 mmol/L
  • increased A1c level of more than 2% from baseline during the study
  • history of angina or heart attack
  • use of ginseng or any natural health products with glucose modulating and/or anti-platelet activity within 2 months
  • BMI > 35 kg/m2 including a weight fluctuation of + 2kg during treatment periods
  • smoke cigarettes; alcohol intake > 2 drinks/day
  • the presence of any conditions which, in the opinion of the investigator, might jeopardize the health and safety of the subject or study personnel or adversely affect the study results, if the subject participated in the study
  • Subjects taking Warfarin or Coumadin, prescription NSAIDs, chronic use of high-dose (>81mg) non-prescription NSAIDs, or selective serotonin reuptake inhibitors and monoamine oxidase inhibitors, or sympathomimetics or medications affecting nitric oxide levels, or any known or suspected sensitivity to any of the ingredients in the test product or placebo cannot participate in the study.

结局指标

主要结局

HbA1c levels and insulin sensitivity index using 3 different indices: ISI, HOMA, QUICKI

时间窗: Weeks -4, 0, 6, 12

次要结局

  • Cholesterol, triglycerides, fasting & post-prandial blood glucose and insulin, C-reactive protein, lipid peroxidation, blood pressure, endothelial function, body fat composition(Weeks -4, 0, 6, 12)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验